Clinical trials: Patients With Tumor
Metastatic Pancreatic Adenocarcinoma
A Study Comparing CO-1.01 With Gemcitabine as First Line Therapy in Patients With Metastatic Pancreatic Adenocarcinoma (LEAP)
The purpose of this study is to determine whether CO-1.01 is safe and effective in the treatment of patients with metastatic pancreatic cancer and low hENT1 expression compared with gemcitabine.
- Trial name
- NCT01124786
- Testing
- CO-1.01, Gemcitabine
- Where
- 95 sites in United States, Argentina and 13 more
- Volunteers
- 367 people
- Sponsor
- Clovis Oncology, Inc.
HER2-positive Breast Cancer
A Study of BL-M07D1 Combined With Pertuzumab Versus Docetaxel Plus Trastuzumab and Pertuzumab in Patients With First-line HER2-positive Recurrent or Metastatic Breast Cancer
This trial is a registrational Phase III, randomized, open-label, multicenter study to evaluate the efficacy and safety of BL-M07D1 combined with Pertuzumab versus docetaxel plus Trastuzumab and Pertuzumab in patients with…
- Trial name
- NCT07518173
- Testing
- BL-M07D1, Pertuzumab, Trastuzumab
- Where
- 2 sites in China
- Volunteers
- 596 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Soft Tissue Sarcoma
Efficacy and Safety of Trabectedin (Yondelis®) in Patients With Advanced Soft Tissue Sarcoma
Efficacy and safety of trabectedin in real-life practice, routinely used for the management of advanced sarcoma after failure of anthracyclines and ifosfamide or patients unsuited to receive these drugs in Germany.
- Trial name
- YonSar (NCT02367924)
- Testing
- trabectedin
- Where
- 19 sites in Germany
- Volunteers
- 130 people
- Sponsor
- PharmaMar, Spain
Advanced or Metastatic Solid Tumors Irrespective of Gene Alterations, Advanced or Metastatic Solid Tumors With Germline PTEN Inactivating Mutations
TAS-117 in Patients With Advanced Solid Tumors Harboring Germline PTEN Mutations
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of TAS-117 in patients with advanced or metastatic solid tumors (excluding primary brain tumors)…
- Trial name
- NCT04770246
- Testing
- TAS-117
- Where
- 8 sites in United States, Austria and 2 more
- Volunteers
- 17 people
- Sponsor
- Taiho Oncology, Inc.
Neoplasm
Human ADME Study of [14C]-Ceralasertib (AZD6738) and Absolute Bioavailability of Ceralasertib
This is an open-label, two-part study in participants with solid tumours and will be conducted at multiple study sites. Participants will be assessed for study eligibility prior to admission to the study site.
- Trial name
- NCT06754761
- Testing
- [14C] AZD6738, AZD6738 / ceralasertib
- Where
- United Kingdom
- Volunteers
- 2 people
- Sponsor
- AstraZeneca
Advanced Pancreatic Adenocarcinoma
A Study to Evaluate [18F]-FDG PET (Fluorodeoxyglucose-positron) in Patients With Pancreatic Cancer (MK-0000-144)
This study will determine whether [18F]-fluorodeoxyglucose-positron emission tomography (FDG-PET) can be used to screen for the activity of novel pancreatic cancer treatments.
- Trial name
- NCT01050283
- Testing
- Comparator: [18F]-FDG PET/CT and Volumetric CT
- Volunteers
- 15 people
- Sponsor
- Merck Sharp & Dohme LLC
Non-small Cell Lung Cancer Metastatic
Efficacy Study of Vx001 Vaccine in NSCLC Patients
Patients with stage IV or recurrent stage I-III NSCLC with documented disease control (objective response or stable disease) within 3 weeks after platinum based 1st line chemotherapy; only HLA-A*0201 positive patients with TERT…
- Trial name
- NCT01935154
- Testing
- Vx-001
- Where
- 70 sites in Czechia, France and 6 more
- Volunteers
- 221 people
- Sponsor
- Vaxon Biotech
Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)
Loncastixumab Tesirine (ADCT-402) Expanded Access Program (EAP) for Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
The EAP is for patients with relapsed/refractory diffuse large b-cell lymphoma (R/R DLBCL) that cannot be treated by currently available drugs, cell therapy, or clinical trials.
- Trial name
- NCT04705454
- Testing
- Loncastuximab Tesirine
- Sponsor
- ADC Therapeutics S.A.
Head and Neck Cancer, Cervical Cancer
A Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies
This is a multicenter, open-label, phase Ib/IIa study. The first part of the study will evaluate the safety, tolerability and preliminary efficacy of ILB2109 and Toripalimab in patients with locally advanced or metastatic solid…
- Conditions
- Head and Neck Cancer, Cervical Cancer, Endometrial Cancer, Triple Negative Breast Cancer
- Trial name
- NCT05955105
- Testing
- ILB-2109, Toripalimab
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Innolake Biopharm
HR Positive/HER-2 Negative Breast Cancer
A Phase Ib/Ⅱ Study of NTQ1062 in Combination With Fulvestrant in Patients With Advanced HR Positive /HER-2 Negative Breast Cancer
This is an open-label, single-arm phase 1b study to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-tumor efficacy of NTQ1062 in combination with Fulvestrant in patients with locally advanced or…
- Trial name
- NCT06172322
- Testing
- NTQ1062 with Fulvestrant
- Where
- China
- Volunteers
- 42 people
- Sponsor
- Nanjing Chia-tai Tianqing Pharmaceutical
Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
This study is to evaluate the safety, tolerability, and PK profiles of Elironrasib and Daraxonrasib as monotherapies and combination therapy in patients with KRAS G12C-mutated solid tumors.
- Conditions
- Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer, Pancreatic Ductal Adenocarcinoma
- Trial name
- NCT06128551
- Testing
- Elironrasib, Daraxonrasib
- Where
- 56 sites in United States, France and 5 more
- Volunteers
- 534 people
- Sponsor
- Revolution Medicines, Inc.
Lymphoma
Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-427 When Given to Patients With Advanced and Refractory Solid Tumors or Lymphoma
This is a phase I, open-label, dose-escalation study of CUDC-427 in patients with advanced or refractory solid tumors or lymphoma.
- Trial name
- NCT01908413
- Testing
- CUDC-427
- Where
- 2 sites in United States
- Volunteers
- 23 people
- Sponsor
- Curis, Inc.
Oral Mucositis
Safety and Efficacy of IZN-6N4 Oral Rinse for the Prevention of Oral Mucositis in Patients With Head and Neck Cancer
The purpose of this study is to determine whether an oral rinse composed of botanical extracts is effective in the prevention of severe inflammation of the lining of the oral cavity caused by chemotherapy and radiation therapy…
- Trial name
- NCT01400620
- Testing
- IZN-6N4
- Where
- 10 sites in United States, Israel
- Volunteers
- 110 people
- Sponsor
- Izun Pharma Ltd
Acute Myelogenous Leukemia, Myelodysplastic Syndrome
Safety and Efficacy Study of PD-616 Plus Cytarabine to Treat Acute Myelogenous Leukemia or Myelodysplastic Syndrome
The purpose of this study is to determine whether PD-616 in combination with low-dose Cytarabine is safe and effective in the treatment of untreated or relapsed/refractory acute myelogenous leukemia (AML) or high-risk…
- Trial name
- AML/MDS (NCT01795924)
- Testing
- PD-616
- Where
- 2 sites in United States
- Volunteers
- 13 people
- Sponsor
- Biosuccess Biotech Co., Ltd.
Advanced Solid Tumor
First-in-Human Study of LPM6690176 in Patients With Advanced Solid Tumors.
This study is a phase 1, first-in-human, open-label, dose-escalation and dose-expansion study designed to evaluate the safety and tolerability, pharmacokinetics characteristics and preliminary anti-tumor activity of LPM6690176…
- Trial name
- NCT06240546
- Testing
- LPM6690176
- Where
- China
- Volunteers
- 102 people
- Sponsor
- Luye Pharma Group Ltd.
Diffuse Large B Cell Lymphoma
Dose Escalation Study in Patients With Relapsed or Refractory DLBCL and MyD88 L265P Mutation
Recent reports have identified a specific oncogenic mutation L265P of the MYD88 gene in approximately 30% of the patients with the activated B-cell (ABC) type of Diffuse Large B Cell Lymphoma (DLBCL).
- Trial name
- NCT02252146
- Testing
- IMO-8400
- Where
- 12 sites in United States
- Volunteers
- 6 people
- Sponsor
- Idera Pharmaceuticals, Inc.
Pain, Bone Neoplasm
A Study to Assess the Efficacy of Intravenous Bondronat (Ibandronate) in Patients With Malignant and Painful Bone Disease
This 2 arm study will compare the efficacy of intravenous Bondronat with that of zoledronic acid in patients with malignant bone disease experiencing moderate to severe pain.
- Conditions
- Pain, Bone Neoplasm, Neoplasm Metastasis
- Trial name
- NCT00099203
- Testing
- ibandronate [Bondronat], zoledronic acid
- Where
- 72 sites in United States, Argentina and 16 more
- Volunteers
- 163 people
- Sponsor
- Hoffmann-La Roche
HIV Infections, Condyloma Acuminata
The Safety and Effectiveness of Cidofovir in the Treatment of Venereal Warts in HIV-Infected Patients
To evaluate the safety and tolerance of topical cidofovir (HPMPC) therapy for condyloma acuminatum in patients with HIV infection.
- Trial name
- NCT00002327
- Testing
- Cidofovir
- Where
- 11 sites in United States
- Volunteers
- 40 people
- Sponsor
- Gilead Sciences
Solid Tumor
Safety Study of PLX108-01 in Patients With Solid Tumors
PLX3397 is a selective inhibitor of Fms, Kit, and oncogenic Flt3 activity. The primary objective of this study is to evaluate the safety and pharmacokinetics of orally administered PLX3397 in patients with advanced, incurable…
- Trial name
- NCT01004861
- Testing
- PLX3397
- Where
- 13 sites in United States
- Volunteers
- 132 people
- Sponsor
- Daiichi Sankyo
Prostate Cancer
R-Flurbiprofen in Treating Patients With Localized Prostate Cancer at Risk of Recurrence
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. R-flurbiprofen may be effective in delaying the recurrence of localized prostate cancer.
- Trial name
- NCT00045123
- Testing
- tarenflurbil, adjuvant therapy
- Where
- 58 sites in United States
- Sponsor
- Myrexis Inc.
The first 5,000 results can be paged through. Add a filter or change the sort order to reach the rest.